Skip to main content

Table 1 Baseline characteristics of the study population

From: Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation

Baseline Characteristics

Whole Cohort

Age (years, mean ± SEM)

44.4 ± 1.2

Gender (n [%] female)

88/103 [85%]

Number of previously tried preventatives (median [95% CI])

7 [7, 8]

Non-responder to botulinum toxin A (n [%])

97/103 [94%]

Current medication overuse

50/103 [49%]

Headache days (median [95% CI])

28 [28 – 28]

Severe headache days (median [95% CI])

15 [12-18]

Current daily headache pattern (n [%])

62/103 [60%]

  1. SEM Standard error of the mean. CI Confidence interval